Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Neoplasia (New York, N.Y.)|September 10, 2017
What's New in SCLC? A ReviewBryan Oronsky, Tony R Reid, Arnold Oronsky, et al.
Seminars in Oncology|July 29, 2020
Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19Bryan Oronsky, Susan Knox, Pedro Cabrales, et al.
American Journal of Cancer Research|November 12, 2021
Toxicology and biodistribution of AdAPT-001, a replication-competent type 5 adenovirus with a trap for the immunosuppressive cytokine, TGF-betaChristopher Larson, Bryan Oronsky, Nacer E Abrouk, et al.
Frontiers in Oncology|February 22, 2021
A Review of Newly Diagnosed GlioblastomaBryan Oronsky, Tony R Reid, Arnold Oronsky, et al.
Discovery Medicine|May 28, 2016
RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cellsBryan Oronsky, Jan Scicinski, Tony Reid, et al.
Oncotarget|January 28, 2016
Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapyBryan Oronsky, Corey Carter, Anna Scicinska, et al.
Oncoimmunology|January 18, 2021
RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"Bryan Oronsky, Corey A Carter, Scott Caroen, et al.
Oncotarget|May 29, 2018
Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cellsBryan Oronsky, Tony R Reid, Arnold Oronsky, et al.
Expert Opinion on Drug Metabolism & Toxicology|January 12, 2021
RRx-001, a downregulator of the CD47- SIRPα checkpoint pathway, does not cause anemia or thrombocytopeniaBryan Oronsky, Pedro Cabrales, Scott Caroen, et al.
Clinical Reviews in Allergy & Immunology|February 20, 2021
A Review of Persistent Post-COVID Syndrome (PPCS)Bryan Oronsky, Christopher Larson, Terese C Hammond, et al.
Pageof 4